The Disease Forecasting Company.
The world’s most trusted independent health intelligence, cited over 16,000 times in 2022
Analysis & Insights
Elderly RSV vaccines to generate $10.5B annually by 2030 in G7 countries
Airfinity releases new forecasts on the market for elderly RSV vaccines in the G7, expecting it to make $900m this year.
Read More →
More from Airfinity
The Post-Pandemic Tripledemic: Forecasting the burden of Influenza, RSV, and COVID-19
How a little-known London start-up predicted China’s deadly Covid outbreak
Airfinity forecasts the severely obese population with metabolic syndrome in the US to grow 50% by 2030 from 26 million to 39.1 million people.
A strong pandemic defence system could reduce the chance of another COVID like pandemic in the next ten years from 27.5% to 8%
Former Editor of The Economist joins Airfinity as advisor
View All →
In the News
Unique Business Interruption policy covers corporates' future pandemic losses
CNBC | Aug 7, 2023
China deletes Covid-19 death data
Financial Times | Jul 18, 2023
Pascal Soriot of AstraZeneca: ‘The climate crisis is a health crisis’
The Guardian | Jul 18, 2023
As China crests second Covid wave, families still mourn victims of the first one
NBC News | Jun 29, 2023
View All →
A pioneer in predictive health intelligence
Understand
What's happening in a given disease area?
Airfinity is the most comprehensive, single source of intelligence for new developments in your chosen area.
Predict
Identify the true need for a vaccine or a treatment.
Our suite of dynamic predictive indicators help you navigate highly dynamic and uncertain market developments and see the real opportunities.
Act
Maximise impact to save lives
Our analytics and probabilistic tools inform key decisions on resource allocation, investment and procurement decisions to maximise impact of a given drug or vaccine and ultimately improve as many lives as possible.
The world's most comprehensive infectious disease solutions.
Airfinity combines proprietary surveillance tools and forecast models with expert analysis for dozens of infectious diseases, including COVID-19, Monkeypox, Influenza and RSV.
OUR PLATFORM:
New science
Market & Production
Policies
Disease & Prevalence
What our users say?
“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”
Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister
“Airfinity has been instrumental in our country's COVID response.”
Head of UK Government
Vaccine Task Force
“Vaccine production data from Airfinity has been spot on. In a fast moving pandemic, these forecasts are really important for evidence-based policy making.”
Director General,
IFPMA
“Airfinity has been critical in furnishing us and the rest of the world with COVID-19 numbers.”
James Fransham, Data Journalist,
The Economist